GGrantIndex
Sort

64,565 grants matching drug discovery

Discovery of Pharmacogenomic Biomarkers for OATP1B1 and OATP1B3

$624,418
Kathleen M Giacomini · University Of California, San Francisco · R01 · FY2020 · GM

Development of Drugs Acting at Adenosine Receptors

$624,412
Kenneth Alan Jacobson · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2019 · DK

WASHINGTON UNIVERSITY CO-CLINICAL IMAGING RESEARCH RESOURCE

$624,395
Kooresh Isaac Shoghi · Washington University · U24 · FY2021 · CA

α9α10 Nicotinic Acetylcholine Receptors in neuropathic pain

$624,360
Andrew Riley · University Of Illinois At Chicago · R01 · FY2025 · NS

α9α10 Nicotinic Acetylcholine Receptors in neuropathic pain

$624,360
Andrew Riley · University Of Illinois At Chicago · R01 · FY2024 · NS

Macrophage Depletion Therapy for Spinal Cord Injury

$624,342
John C Gensel · University Of Kentucky · R01 · FY2022 · NS

UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program

$624,326
Kim L Brouwer · Univ Of North Carolina Chapel Hill · T32 · FY2017 · GM

Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers

$624,299
William C Hahn · Broad Institute, Inc. · R01 · FY2024 · CA

Breaching the Gram negative bacterial cellular envelope

$624,267
Yinan Wei · Texas A&M University Health Science Ctr · R01 · FY2025 · AI

Dysregulation of Histone Acetylation in Parkinson's Disease

$624,231
Frank Soldner · Albert Einstein College Of Medicine · R56 · FY2023 · NS

Structures of Mtb proteins conferring susceptibility to known Mtb inhibitors

$624,230
James C Sacchettini · Texas A&M University · U01 · FY2011 · GM

Molecular Genetics of HSV DNA Polymerase Gene

$624,224
Donald M Coen · Harvard Medical School · R56 · FY2017 · AI

Drug Development for Prostate Cancer and other Metastatic Processes

$624,197
William Douglas Figg · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA

Risk Prediction for ER Negative Breast Cancer Recurrence

$624,192
Melissa L Bondy · Baylor College Of Medicine · R01 · FY2015 · CA

Preclinical Assays of Hippocampal-Prefrontal Cortical Circuit Engagement for Application in Therapeutic Development

$624,149
Andrew Porter Maurer · University Of Florida · R01 · FY2023 · MH

PLEKHA7 A Novel Target for Mutant KRAS Therapy

$624,131
Garth Powis · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2017 · CA

PLEKHA7 A Novel Target for Mutant KRAS Therapy

$624,131
Garth Powis · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2018 · CA

PLEKHA7 A Novel Target for Mutant KRAS Therapy

$624,131
Garth Powis · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2016 · CA

PLEKHA7 A Novel Target for Mutant KRAS Therapy

$624,131
Garth Powis · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2015 · CA

Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads

$624,004
John M Littleton · Naprogenix, Inc · R44 · FY2020 · NS

Cannabinoid CB2 Receptor Structure and Allosteric Modulators

$623,964
Xiang-Qun Xie · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · DA

2024 SenNet CODCC Supplement

$623,959
Jonathan C. Silverstein · University Of Pittsburgh At Pittsburgh · U24 · FY2024 · CA

High Throughput Screening for Pharmacoperones of the V2 Receptor

$623,890
Jo Ann Janovick · Texas Tech University Health Scis Center · R01 · FY2015 · DK

PRETARGETING WITH ANTI-CEA MABS FOR THERAPY

$623,885
Paul Yazaki · Beckman Research Institute/City Of Hope · P01 · FY2008 · CA

NEW APPROACHES TO TARGET SPECIFIC ANTIFUNGAL AGENTS

$623,834
Georgetown University · R01 · FY2000 · CA